Loading organizations...
§ Private Profile · Guilford, CT, USA
Tesseract Health is a technology company.
identifeye HEALTH, formerly Tesseract Health, develops advanced retinal imaging systems for non-invasive disease detection. Its platform streamlines high-quality fundus image capture, integrating efficiently into clinical settings. Leveraging the retina’s unique properties:as the only body area where nerves and blood vessels are directly visible:the company provides systemic health insights.
Dr. Jonathan Rothberg, a serial medical technology entrepreneur, founded the company in 2018. His insight centered on the eye's potential for extensive diagnostic information. Rothberg aimed to democratize global healthcare by making sophisticated, non-invasive retinal examination capabilities widely accessible for early and thorough health assessment.
The company’s products are utilized in fast-paced healthcare environments, empowering practitioners with robust tools for patient evaluation. identifeye HEALTH aims to improve health outcomes through earlier disease identification across various conditions. Its long-term vision involves deploying AI-powered screening and monitoring tools to deliver advanced clinical insights directly at the point-of-care, expanding diagnostic reach.
Tesseract Health has raised $80.0M across 1 funding round.
Tesseract Health has raised $80.0M in total across 1 funding round.
Tesseract Health is a health technology company developing portable, AI-powered retinal imaging devices to enable non-invasive disease detection and monitoring through the eye, without drawing blood.[1][2][3] Founded in 2018 and headquartered in Guilford, CT, it builds the Tesseract iC™ platform, a binocular device combining multidimensional sensors, advanced imaging, and AI algorithms to democratize healthcare by providing affordable, point-of-care diagnostics for conditions like diabetes, Alzheimer's, heart disease, and cancer, serving primary care providers, patients in underserved areas, and global telemedicine.[1][3][5] The company addresses barriers of costly, inaccessible tools by offering intuitive, operable-by-anyone devices that leverage the retina as a "window to the body," with strong growth from an oversubscribed $80 million Series B in 2021 backed by investors like Foresite Capital and part of the 4Catalyzer accelerator.[4][7][8]
Tesseract Health was founded in 2018 by Dr. Jonathan Rothberg, a serial entrepreneur known for innovations in genomics and diagnostics, with the vision to create a new diagnostic paradigm using the retina's rich health data.[3][5][7] The idea emerged from recognizing the eye's potential as a noninvasive platform—directly viewing arteries, veins, capillaries, and nerves—to predict and monitor diseases early, inspired by Rothberg's drive to promote health equity globally.[1][3][6] In 2021, Dr. Vasiliki (Vicky) Demas, a Ph.D. in Chemical Engineering from UC Berkeley with postdoctoral experience at national labs, joined as CEO to lead development of the Tesseract iC platform, accelerating tech advancement and regulatory pursuits.[1][3] Early traction included integration into 4Catalyzer, alongside successes like Butterfly Network, and the $80 million Series B to fund AI enhancements and commercialization.[3][4][7]
Tesseract rides the wave of AI-driven precision diagnostics and telehealth expansion, capitalizing on post-COVID demand for remote, equitable care amid aging populations and chronic disease burdens.[2][5][7] Timing aligns with AI advances enabling accurate retinal predictions of systemic risks like heart attacks or neurodegeneration, disrupting traditional radiology and lab medicine with a unified platform.[1][3][5] Market forces favoring it include rising healthcare costs, portability needs in underserved areas, and regulatory pushes for noninvasive tech, positioning Tesseract to influence ecosystems by enabling early interventions globally via 4Catalyzer's network (e.g., Butterfly Network's ultrasound success).[3][5][7]
Tesseract is poised for FDA clearance, commercial launch, and expansion into IPO territory, building on Series B momentum to scale AI models and global distribution.[4][5][7] Trends like AI integration in wearables, health equity initiatives, and multimodal diagnostics will propel it, potentially evolving from eye-focused screening to a core telemedicine staple. As Rothberg envisions, its influence could redefine accessible healthcare, fulfilling the founding mission to make lifesaving insights universal.[3][6] This positions Tesseract as a pivotal player in revolutionizing patient monitoring from the eye outward.
Tesseract Health has raised $80.0M across 1 funding round. Most recently, it raised $80.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2021 | $80M Series B | — | ARCH Venture Partners, Foresite Capital, Krishna Yeshwant, Vzvc, Larry Robbins, Opaleye Management | Announced |
Tesseract Health has raised $80.0M in total across 1 funding round.
Tesseract Health's investors include ARCH Venture Partners, Foresite Capital, Krishna Yeshwant, VZVC, Larry Robbins, Opaleye Management.